UNICREDIT BANK/CALL/NOVO-NORDISK B/900/0.2/18.12.24 | Real-time BOERSE MUENCHEN 08:45:38 03/07/2024 BST | ||
| 3.82 EUR | -3.29% |
|
| Current month | -4.82% | ||
| 1 month | +36.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 3.82 | -3.29% |
| 02/07/24 | 3.95 | -8.56% |
| 01/07/24 | 4.32 | +4.10% |
| 28/06/24 | 4.15 | -1.43% |
| 27/06/24 | 4.21 | 0.00% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 08:45 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC7P3C |
| ISIN | DE000HC7P3C1 |
| Date issued | 26/06/2023 |
| Strike | 900 kr |
| Maturity | 18/12/2024 (169 Days) |
| Parity | 5 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.63 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.03 € |
| Spread % | 0.79% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
